Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Quisnon dispersion tablet

A technology of prulifloxacin and dispersible tablets, which can be applied in the directions of organic active ingredients, medical preparations containing active ingredients, and pill delivery, etc., can solve the problems of unsatisfactory pharmacokinetics and safety, etc.

Inactive Publication Date: 2008-04-16
TIANJIN HANKANG PHARMA BIOTECH
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] The international academic community divides the research and development of quinolones into four stages: the first stage is the initial stage of development, in the 1970s, the main products are nalidixic acid, pipemidic acid, etc. The activity of Lambert-negative bacteria, and the pharmacokinetics and safety are not satisfactory, and it is basically an obsolete species

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Quisnon dispersion tablet
  • Quisnon dispersion tablet
  • Quisnon dispersion tablet

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0112] Prulifloxacin 132.1g (approximately equivalent to 100g of the active ingredient)

[0113] Lactose 100g

[0114] Microcrystalline Cellulose 100g

[0115] Sodium carboxymethyl starch 34g

[0116] Povidone 10g

[0117] Talc powder 2g

[0118]

[0119] Makes 1000 pieces

[0120] Preparation

[0121] 1 Preparation and processing of raw materials:

[0122] The prulifloxacin, lactose, microcrystalline cellulose, carboxymethyl starch sodium, and povidone were respectively pulverized and passed through a 300-mesh sieve for later use.

[0123] 2 Weighing and mixing:

[0124] 2.1 Weigh the above-mentioned raw and auxiliary materials according to the prescription amount and calculate the feeding amount after double checking.

[0125] 2.2 Mix the above raw and auxiliary materials evenly.

[0126] 3 Granulation:

[0127] 3.1 Press it into a 0.5g tablet first, and control the hardness at 3-4kg; then use a swing granulator and a 24-mesh sc...

Embodiment 2

[0138] Prulifloxacin 100g

[0139] Lactose 50g

[0140] Microcrystalline Cellulose 50g

[0141] Sodium carboxymethyl starch 17g

[0142] Povidone 5g

[0143] Talc powder 1g

[0144]

[0145] Makes 1000 pieces

[0146] Preparation method is the same as embodiment 1

Embodiment 3

[0148] Prulifloxacin 200g

[0149] Lactose 200g

[0150] Microcrystalline Cellulose 200g

[0151] Sodium carboxymethyl starch 68g

[0152] Povidone 20g

[0153] Talc powder 4g

[0154]

[0155] Makes 1000 pieces

[0156] Preparation method is the same as embodiment 1

[0157]

[0158]

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a dispersible tablet preparation containing antiseptic Prulifloxacin, wherein the constituents of the preparation include Prulifloxacin, lactose, crystalline cellulose, sodium carboxymethylstarch, polyvidone and talcum powder.

Description

technical field [0001] The present invention relates to a pharmaceutical preparation, in particular to a new pharmaceutical preparation containing the antibacterial agent prulifloxacin, which consists of: prulifloxacin, lactose, microcrystalline cellulose, sodium carboxymethyl starch, povidone, and talc pink. Background technique [0002] Infectious disease is the most common clinical disease, involving almost all clinical specialties, and it is also one of the most common causes of patient death. According to the report of the World Health Organization in 1997, the number of deaths from infectious diseases was as high as 33.3% of the total number of deaths from various causes. In my country, due to the large rural population and the still backward medical insurance system, the main diseases that endanger people's health are still infectious diseases caused by various pathogenic bacteria, and are also the main cause of disability and death. [0003] Anti-infective drugs ar...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K9/20A61K31/496A61P31/04
Inventor 严洁
Owner TIANJIN HANKANG PHARMA BIOTECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com